# Pembrolizumab and Imatinib in Patients With Locally Advanced/Metastatic Melanoma With c-KIT Mutation/Amplification

> **NCT02812693** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Joanne Jeter**

## Conditions studied

- Stage IIIA Skin Melanoma
- Stage IIIB Skin Melanoma
- Stage IIIC Skin Melanoma
- Stage IV Skin Melanoma

## Interventions

- **DRUG:** Imatinib Mesylate
- **OTHER:** Laboratory Biomarker Analysis
- **BIOLOGICAL:** Pembrolizumab

## Key facts

- **NCT ID:** NCT02812693
- **Lead sponsor:** Joanne Jeter
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2016-11-04
- **Primary completion:** 2017-11-20
- **Final completion:** 2017-11-20
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** poor accrual
- **Last updated:** 2018-04-05

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02812693

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02812693, "Pembrolizumab and Imatinib in Patients With Locally Advanced/Metastatic Melanoma With c-KIT Mutation/Amplification". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02812693. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*